BR112012001551A2 - profármacos de aminoácido galantamina e peptídeo e usos dos mesmos - Google Patents

profármacos de aminoácido galantamina e peptídeo e usos dos mesmos

Info

Publication number
BR112012001551A2
BR112012001551A2 BR112012001551A BR112012001551A BR112012001551A2 BR 112012001551 A2 BR112012001551 A2 BR 112012001551A2 BR 112012001551 A BR112012001551 A BR 112012001551A BR 112012001551 A BR112012001551 A BR 112012001551A BR 112012001551 A2 BR112012001551 A2 BR 112012001551A2
Authority
BR
Brazil
Prior art keywords
galantamine
amino acid
peptide amino
acid prodrugs
prodrugs
Prior art date
Application number
BR112012001551A
Other languages
English (en)
Inventor
T Golding Bernard
Franklin Richard
g tyson Robert
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Publication of BR112012001551A2 publication Critical patent/BR112012001551A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91Dibenzofurans; Hydrogenated dibenzofurans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012001551A 2009-07-23 2010-07-23 profármacos de aminoácido galantamina e peptídeo e usos dos mesmos BR112012001551A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22801409P 2009-07-23 2009-07-23
PCT/US2010/043166 WO2011011766A1 (en) 2009-07-23 2010-07-23 Galantamine amino acid and peptide prodrugs and uses thereof

Publications (1)

Publication Number Publication Date
BR112012001551A2 true BR112012001551A2 (pt) 2017-07-11

Family

ID=42569670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001551A BR112012001551A2 (pt) 2009-07-23 2010-07-23 profármacos de aminoácido galantamina e peptídeo e usos dos mesmos

Country Status (11)

Country Link
US (2) US20110098278A1 (pt)
EP (1) EP2456434A1 (pt)
JP (1) JP2013500268A (pt)
KR (1) KR20120046268A (pt)
CN (1) CN102625700A (pt)
AU (1) AU2010275431A1 (pt)
BR (1) BR112012001551A2 (pt)
CA (1) CA2768668A1 (pt)
MX (1) MX2012000939A (pt)
RU (1) RU2012106605A (pt)
WO (1) WO2011011766A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046062A1 (en) * 2010-10-05 2012-04-12 Shire, Llc Use of prodrugs to avoid gi mediated adverse events
GB201019525D0 (en) * 2010-11-18 2010-12-29 Shire Llc Oil-based formulations
WO2013035053A2 (en) * 2011-09-09 2013-03-14 Kareus Therapeutics, Sa Novel conjugation-facilitated transport of drugs across blood brain barrier
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CA2944019C (en) 2014-03-25 2022-08-02 Synaptec Development Llc Treatment of autism
JP6738797B2 (ja) * 2014-03-25 2020-08-12 イーエムアイシーアイピーアイ・エルエルシーEmicipi Llc レット症候群治療薬
EP3142669A2 (en) 2014-05-16 2017-03-22 Synaptec Development LLC CLEARANCE OF AMYLOID ß
CN115504893B (zh) * 2022-11-18 2023-03-10 成都普康生物科技有限公司 一种L-谷氨酸-α-叔丁酯的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AU1282099A (en) * 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
CA2393301A1 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20090253654A1 (en) * 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1937226A2 (en) 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
EP2091914A4 (en) * 2006-11-08 2010-12-29 Chongxi Yu TRANSDERMAL ADMINISTRATION SYSTEMS FOR PEPTIDES AND RELATED CONNECTIONS
US9023860B2 (en) * 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
DK2250163T3 (da) * 2008-02-12 2012-07-16 Bristol Myers Squibb Co Hepatitis C-virusinhibitorer
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
AT507039A1 (de) * 2008-06-26 2010-01-15 Sanochemia Pharmazeutika Ag Verfahren zum herstellen von hochreinen benzazepinderivaten

Also Published As

Publication number Publication date
MX2012000939A (es) 2012-06-08
US20110098278A1 (en) 2011-04-28
US20120184532A1 (en) 2012-07-19
CN102625700A (zh) 2012-08-01
KR20120046268A (ko) 2012-05-09
JP2013500268A (ja) 2013-01-07
AU2010275431A1 (en) 2012-02-23
RU2012106605A (ru) 2013-08-27
EP2456434A1 (en) 2012-05-30
WO2011011766A1 (en) 2011-01-27
CA2768668A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
BR112012001164A2 (pt) aminoácido de carbamato e pró-fármacos de peptídeo de opioides e usos dos mesmos
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos
BRPI0923283A2 (pt) conjugados terapêuticos de peptídeo e usos dos mesmos
BRPI1015918A2 (pt) conjugados de peptídeo multiméricos e usos dos mesmos
BRPI0912225A2 (pt) peptídeos de direcionamento lisossomais e usos dos mesmos
BR112012001551A2 (pt) profármacos de aminoácido galantamina e peptídeo e usos dos mesmos
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
BRPI1011404A2 (pt) mutantes e usos dos mesmos
HK1168353A1 (en) Alkylamine substituted dicyanopyridine and amino acid ester prodrugs thereof
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
BR112013013167A2 (pt) inibidores de bromodomínio e usos dos mesmos
BRPI1011710A2 (pt) lágrimas artificiais e usos trapêuticos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BR112013021524A2 (pt) micro-organismos recombinantes e usos dos mesmos
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BRPI1015238A2 (pt) diamidas de azetidilina como inibidores de monoaciglicerol lipase
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
SMT201400069B (it) Formulazione farmaceutica
ES2769357T8 (es) Formas farmacéuticas de apixaban
BRPI1009197A2 (pt) preparação de ácido alfa-cetopimélico
BR112012002072A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
BRPI1006863A2 (pt) composições de vacina e plasmodium purificado

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]